Articlenpj biomedical innovations2025
The convergence of AI and synthetic biology: the looming deluge.
Article in npj biomedical innovations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- AI for bioactive materials: From material design to biological applications.Bioactive materials · 2026Review
- Challenges and Future Directives of Synthetic Biology in Engineering Plant-Microbe Partnerships for Sustainable Agriculture.Biotechnology and bioengineering · 2026Review
- Rethinking non-human primate models for emerging viral infections after COVID-19.Laboratory animal research · 2026Review
- Artificial intelligence-driven advancements in agricultural biotechnology.Journal, genetic engineering & biotechnology · 2026Review
- Navigating regulatory fragmentation in the convergence of synthetic biology, artificial intelligence, and automation.Nature communications · 2026Review
- Enhanced classification and identification of bacterial and viral microorganisms by integration of MALDI-TOF mass spectrometry with artificial intelligence.Scientific reports · 2026Article
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- The time window before biological AI spreads : To prevent the misuse of biological AI models with dual-use capabilities requires governance of the embargo window.EMBO reports · 2026Article
- Microbial production of xanthohumol driven by synthetic biology approaches.World journal of microbiology & biotechnology · 2026Review
- Leveraging AI and integrated genomic-enviromic prediction for intelligent sugarcane breeding.Plant communications · 2026Review
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Genome mining strategies to unlock the metabolic potential ofFrontiers in microbiology · 2026Article
- Article
- AI-assisted crop improvement: new design tools within established regulatory frameworks.Frontiers in plant science · 2026Article
- Integrated multi-omics and genome mining strategies for activating cryptic polyketide biosynthetic gene clusters inFrontiers in microbiology · 2026Review
- Improving governance in the age of synthetic biology, artificial intelligence, and diverging threats.Frontiers in bioengineering and biotechnology · 2026Article
- Programmable synthetic engineering of adaptive microbial cell factories: from amide transforming enzymes to advanced biocatalytic systems.Frontiers in bioengineering and biotechnology · 2026Review
- Governing synthetic biology and artificial intelligence (AI) convergence: emerging biosecurity priorities for Africa.Frontiers in bioengineering and biotechnology · 2026Review
- Virologist Opinions: An Important Component for the Governance of the Convergence of Artificial Intelligence and Dual-Use Research of Concern.Applied biosafety : journal of the American Biological Safety Association · 2025Article
- From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats.Frontiers in public health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The convergence of AI and synthetic biology is revolutionizing biological discovery and engineering. This manuscript examines how AI-driven tools accelerate bioengineering workflows, unlocking innovations in medicine, agriculture, and sustainability. It also addresses dual-use risks, governance gaps, and ethical dilemmas posed by these advancements, proposing strategies for oversight and updated regulations. By exploring opportunities and risks, this work highlights the transformative potential of AI-driven synthetic biology and pathways for responsible development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.